Exploring Diagnostic Markers and Therapeutic Targets in Parkinson’s Disease: A Comprehensive 1 H-NMR Metabolomic Analysis – Systematic Review
Archivum Immunologiae et Therapiae Experimentalis · 2025
DOI: 10.2478/aite-2025-0011 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2025. Verfasst von Andrzej Wasilewski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Student Scientific Association of Medical Chemistry and Immunochemistry, Wroclaw Medical University, Wroclaw, Poland. Hauptthemen laut MEDLINE: Parkinson Disease, Metabolomics, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Parkinson’s disease (PD) affects millions of people globally. Accurate early diagnosis remains a challenge due to the lack of specific biomarkers. This systematic review explores the potential of 1 H-NMR metabolomics in identifying diagnostic markers and therapeutic targets for PD. A comprehensive analysis was conducted across databases such as Scopus, Web of Science, PubMed, and Embase, focusing on studies that utilized 1 H-NMR spectroscopy to profile metabolites associated with PD progression. The review identifies key metabolites—glutamate, taurine, myo-inositol, glutamine, and creatine—that play critical roles in the pathophysiology of PD. Glutamate, linked to excitotoxicity and neuronal degeneration, emerges as a prominent target for therapeutic intervention, while taurine is associated with oxidative stress. Myo-inositol, a key regulator of autophagy, underscores the biochemical dysregulation associated with PD, similar to glutamine and glutamate. Creatine’s role in neuronal energy metabolism suggests potential avenues for treatment focused on energy supplementation. The reproducibility of metabolite findings varied, indicating the complexity of PD’s metabolomic landscape. Despite challenges in consistency, these metabolites hold promise as biomarkers for diagnosing PD and tracking disease progression. The review underscores the need for further validation of these markers and their integration with other omics technologies to enhance PD management. By identifying key metabolic pathways, this study opens new directions for personalized medicine, offering potential therapeutic targets to slow disease progression and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Scientific Association of Medical Chemistry and Immunochemistry, Wroclaw Medical University, Wroclaw, Poland.
- Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland.
- Department of Allergology, Medical University of Gdansk, Gdansk, Poland.
- Center of Rare Disease, Centre University Hospital, Gdansk, Poland.
- Department of Immunochemistry and Chemistry, Wroclaw Medical University, Wroclaw, Poland.
Zitieren
APA
Wasilewski, A., Wasilewska, E., & Serrafi, A. (2025). Exploring Diagnostic Markers and Therapeutic Targets in Parkinson’s Disease: A Comprehensive 1 H-NMR Metabolomic Analysis – Systematic Review. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2025-0011
Vancouver
Wasilewski A, Wasilewska E, Serrafi A. Exploring Diagnostic Markers and Therapeutic Targets in Parkinson’s Disease: A Comprehensive 1 H-NMR Metabolomic Analysis – Systematic Review. Archivum Immunologiae et Therapiae Experimentalis. 2025. doi:10.2478/aite-2025-0011
BibTeX
@article{Wasilewski2025,
author = {Wasilewski, Andrzej and Wasilewska, Eliza and Serrafi, Agata},
title = {Exploring Diagnostic Markers and Therapeutic Targets in Parkinson’s Disease: A Comprehensive 1 H-NMR Metabolomic Analysis – Systematic Review},
journal = {Archivum Immunologiae et Therapiae Experimentalis},
year = {2025},
doi = {10.2478/aite-2025-0011}
}
EUVIMED